SRT3 Stock Overview
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sartorius Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €329.70 |
| 52 Week High | €383.70 |
| 52 Week Low | €215.30 |
| Beta | 0.84 |
| 1 Month Change | -9.55% |
| 3 Month Change | 11.35% |
| 1 Year Change | -4.41% |
| 3 Year Change | -28.71% |
| 5 Year Change | 105.93% |
| Change since IPO | 586.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| SRT3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -4.6% | -2.9% | -2.5% |
| 1Y | -4.4% | -9.5% | -0.4% |
Return vs Industry: SRT3 underperformed the German Life Sciences industry which returned -9.5% over the past year.
Return vs Market: SRT3 underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| SRT3 volatility | |
|---|---|
| SRT3 Average Weekly Movement | 4.8% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SRT3's share price has been volatile over the past 3 months.
Volatility Over Time: SRT3's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 14,614 | Joachim Kreuzburg | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products.
Sartorius Aktiengesellschaft Fundamentals Summary
| SRT3 fundamental statistics | |
|---|---|
| Market cap | €19.98b |
| Earnings (TTM) | €205.20m |
| Revenue (TTM) | €3.40b |
110.9x
P/E Ratio6.7x
P/S RatioIs SRT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRT3 income statement (TTM) | |
|---|---|
| Revenue | €3.40b |
| Cost of Revenue | €1.83b |
| Gross Profit | €1.57b |
| Other Expenses | €1.36b |
| Earnings | €205.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 19, 2024
| Earnings per share (EPS) | 2.97 |
| Gross Margin | 46.15% |
| Net Profit Margin | 6.04% |
| Debt/Equity Ratio | 187.3% |
How did SRT3 perform over the long term?
See historical performance and comparison